Previously, we compared response to MET and MEK inhibition in tumor xenografts derived from MPNSTs of genetically engineered mouse models of NF1, including a Met-amplified, Trp53-wildtype model (NF1-MET; genotype: Nf1fl/ko;lox-stop-loxMETtg/+;Plp-creERTtg/+) and a Trp53 deficient model (NF1-P53; genotype: Nf1ko/+;p53R172H;Plp-creERTtg/+). The gene discussed is MET; the disease is neoplasm.